Form 8-K - Current report:
SEC Accession No. 0001193125-25-158192
Filing Date
2025-07-11
Accepted
2025-07-11 16:01:26
Documents
13
Period of Report
2025-07-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d83413d8k.htm   iXBRL 8-K 33723
2 EX-3.1 d83413dex31.htm EX-3.1 5774
  Complete submission text file 0001193125-25-158192.txt   161938

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250708.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250708_lab.xml EX-101.LAB 18740
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250708_pre.xml EX-101.PRE 11712
16 EXTRACTED XBRL INSTANCE DOCUMENT d83413d8k_htm.xml XML 3885
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 251118976
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)